Why choose Olink for targeted protein biomarker discovery?
In profiling the immune systems of newborn children, the Olink panels allow us to maximize the amount of information extracted from a few microliters of plasma.
Assistant Professor Petter Brodin
Department of Medicine, Karolinska Institute, Stockholm
I am very pleased with the Olink methodology, which has revealed several new biomarkers in the CSF and plasma from patients with multiple sclerosis. It was of particular interest to be able to detect markers in plasma that reflect neuronal damage, including neurofilament light chains
Professor Tomas Olsson
Center for Molecular Medicine, Karolinska Hospital, Stockholm
Olink’s immunoassay panels are very useful tools for targeting and discovering protein dynamics in our longitudinal studies, such as the integrative personal omics profile (iPOP)
Professor Mike Snyder
Department of Genetics, Stanford University
The Olink panel provided some directions we wouldn’t have considered previously, and is a very appealing strategy for neuroscience projects hoping to identify novel CSF biomarkers
Principal Scientist, Pfizer Neuroscience
We have employed Olink panels in longitudinal deep phenotyping studies of over 5,000 individuals. We have found the data quality and reproducibility to be among the best of the high dimensional data strategies we have used.
Professor Leroy Hood
Institute for Systems Biology, Seattle
We are impressed by the quality of data delivered by the Olink technology with very small sample sizes. The application in the field of precision medicine is extremely promising.
Professor Mathias Uhlen
Science for Life Laboratory & Royal Institute of Technology (KTH), Stockholm
Olink has developed a very innovative technology that has a simplicity approach to be able to measure large numbers of proteins. That’s a significant breakthrough for investigators to break into a field of diseases that you could not explore without this technology.
Professor C.Thomas Caskey
Baylor College of Medicine, Houston TX
Available now – a new oncology panel
Olink® ONCOLOGY III offers a combination of established and exploratory protein biomarkers focused on oncology, and is available for immediate shipment as kits, or via our Analysis Service. This panel provides a perfect complement to our existing panel, Olink® ONCOLOGY II, which together now enable oncologists to measure 184 proteins in two dedicated panels. This also extends our total library of thoroughly validated protein assays to 1164.
News & Events Highlights
View the video and get a flavor of the major international meeting, “Precision Proteomics to Drive Personalized Medicine“, which Olink arranged at the Nobel Forum in Stockholm on June 19, 2018. This global event brought together leading scientists from both academia and industry to listen to a series of outstanding presentations and to engage in important discussions around the increasing importance of protein biomarkers for the development of more personalized healthcare.